Predictors of Health Utility in Relapsing–Remitting and Secondary-Progressive Multiple Sclerosis: Implications for Future Economic Models of Disease-Modifying Therapies
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-2027
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Predictors of Health Utility in Relapsing–Remitting and Secondary-Progressive Multiple Sclerosis: Implications for Future Economic Models of Disease-Modifying Therapies ; day:29 ; month:9 ; year:2020 ; pages:1-14
PharmacoEconomics ; (29.9.2020), 1-14
- Creator
-
Hernandez, Luis
O’Donnell, Malinda
Postma, Maarten
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40273-020-00964-w
- URN
-
urn:nbn:de:101:1-2020111617470549014338
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:37 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Hernandez, Luis
- O’Donnell, Malinda
- Postma, Maarten
- SpringerLink (Online service)
Other Objects (12)
The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review
Relapsing/remitting type 1 diabetes
Cost-utility and cost-effectiveness analysis of disease-modifying drugs of relapsing–remitting multiple sclerosis: a systematic review
Cost and effectiveness of autologous haematopoietic stem cell transplantation and high-efficacy disease-modifying therapies in relapsing–remitting multiple sclerosis
Endocarditis following ocrelizumab in relapsing-remitting MS
Postural Control in Relapsing-Remitting Multiple Sclerosis
Cost Per Relapse Avoided for Ozanimod Versus Other Selected Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis in the United States
Relapsing–remitting painful ophthalmoplegia due to orbital myositis
Abnormal multisensory integration in relapsing–remitting multiple sclerosis
Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis
A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial
Longitudinal cortical network reorganization in early relapsing–remitting multiple sclerosis
The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review
Relapsing/remitting type 1 diabetes
Cost-utility and cost-effectiveness analysis of disease-modifying drugs of relapsing–remitting multiple sclerosis: a systematic review
Cost and effectiveness of autologous haematopoietic stem cell transplantation and high-efficacy disease-modifying therapies in relapsing–remitting multiple sclerosis
Endocarditis following ocrelizumab in relapsing-remitting MS
Postural Control in Relapsing-Remitting Multiple Sclerosis
Cost Per Relapse Avoided for Ozanimod Versus Other Selected Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis in the United States
Relapsing–remitting painful ophthalmoplegia due to orbital myositis
Abnormal multisensory integration in relapsing–remitting multiple sclerosis
Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis
A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial
Longitudinal cortical network reorganization in early relapsing–remitting multiple sclerosis
The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review
Relapsing/remitting type 1 diabetes
Cost-utility and cost-effectiveness analysis of disease-modifying drugs of relapsing–remitting multiple sclerosis: a systematic review
Cost and effectiveness of autologous haematopoietic stem cell transplantation and high-efficacy disease-modifying therapies in relapsing–remitting multiple sclerosis
Endocarditis following ocrelizumab in relapsing-remitting MS
Postural Control in Relapsing-Remitting Multiple Sclerosis
Cost Per Relapse Avoided for Ozanimod Versus Other Selected Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis in the United States
Relapsing–remitting painful ophthalmoplegia due to orbital myositis
Abnormal multisensory integration in relapsing–remitting multiple sclerosis
Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis
A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial